The FARETINA-AMD study group assessed approximately 23,000 patients with wet AMD who had received at least one dose of faricimab (Vabysmo, Genentech/Roche). What have they found? Sophie Bakri, MD, summarizes the findings of an IRIS Registry review, which uncovered data about who has been dosed with faricimab, how frequently extended dosing intervals have been achieved, and whether real-world safety issues have cropped up. 

And Karl Csaky, MD, PhD, offers a glimpse into the future of geographic atrophy care. Are any budding technologies better able to assess structure and function in GA patients? Keep it here to find out. 

This Editorially independent content is supported with advertising.